Last update 20 Jun 2026

Fusion-VAC-XS15

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
DNAJB1-PRKACA Fusion Transcript-based Peptide(University Hospital Tuebingen), Fusion Transcript-based Peptide Vaccine(University Hospital Tuebingen), FusionVAC-XS15
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
NeoplasmsDigestive System DisordersOther Diseases
Active Indication
Fibrolamellar Hepatocellular Carcinoma
Inactive Indication-
Originator Organization
University Hospital TübingenUniversity Hospital Tübingen
Active Organization
University Hospital TübingenUniversity Hospital Tübingen
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Fusion-VAC-XS15
NCT06789198
/ RecruitingPhase 1IIT
FusionVAC22_02: DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Oncogenic Driver Fusion
NCT05937295
/ RecruitingPhase 1IIT
FusionVAC22_01: DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition for Fibrolamellar Hepatocellular Carcinoma and Other Tumor Entities Carrying the Oncogenic Driver Fusion
100 Clinical Results associated with Fusion-VAC-XS15
Login to view more data
100 Translational Medicine associated with Fusion-VAC-XS15
Login to view more data
100 Patents (Medical) associated with Fusion-VAC-XS15
Login to view more data
100 Deals associated with Fusion-VAC-XS15
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrolamellar Hepatocellular CarcinomaPhase 1
Germany
University Hospital TübingenUniversity Hospital Tübingen
26 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06789198 (FusionVAC22_02, ASCO2026)
Phase 1
Fibrolamellar Hepatocellular Carcinoma
Adjuvant
DNAJB1-PRKACA fusion transcript
20
(DNAJB1-PRKACA fusion transcript + FLC or other DNAJB1-PRKACA fusion-positive cancers)
ngvjqblvmm(tzseglfqcs) = jwurwfikoa hvsfmqccez (sxuujjklko )
Positive
29 May 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free